379. This Month in MedTech 2026: Cardiovascular M&A, Medtronic’s $100M Bet, and the Platform Wars

In this episode of This Month in MedTech 2026, April brings a sharper look at where the market is heading.The discussion covers Medtronic’s $100M investment in Pulnovo, why denervation may be turning into a platform strategy, and how China market access could become a bigger part of global MedTech dealmaking. The episode also unpacks Q1 funding trends, cardiovascular M&A, and key deals across thrombectomy, oncology, metabolic disease, lung cancer, and wearable robotics. The bigger message is clear: capital is still moving, but it is becoming more strategic.This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.Episode Breakdown:00:00 Q1 2026 MedTech Funding Drops Explained00:55 Intro + This Month in MedTech02:13 Q1 2026 Funding Recap04:14 Why Capital Deployment Slowed Down06:10 Mega Rounds Decline Explained06:58 Early Stage MedTech Funding Still Stable07:46 MarketCraft Ad: Engineering Market Pull11:01 LSI Alumni and Early Stage Funding Trends12:01 Cardiovascular M&A Momentum13:22 Stryker’s Surprise Cardiovascular Strategy15:48 Endovascular Robotics and Platform Wars18:36 IVL Market Growth + Strategic Acquisitions19:59 Medtronic’s $100M Bet on Pulnovo21:00 Why Medtronic is Suddenly Aggressive22:11 Boston Scientific vs Medtronic Strategy24:33 Future of Early Stage MedTech Investing25:54 AI in MedTech Companies27:17 Pulnovo Technology Explained28:38 China Market Access Strategy30:38 Platform Strategy in MedTech32:46 Deals and Dollars Speed Round33:21 Cala Health $50M Growth Round34:03 Calyxo $40M Series F Explained35:25 Endovascular Engineering $80M Series C39:20 Sonera Therapeutics Series A40:27 Endogenex and Metabolic Device Innovation43:02 GLP-1 Drugs vs Device-Based Therapies44:25 Hepa Medical Lung Cancer Technology45:21 Wearable Robotics and Exoskeleton Market47:34 Biggest Takeaways from April 202648:49 Why Platform Companies Are Winning49:40 Free Trial for Compass AI51:07 Final Thoughts + Outro  Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GrowMyMedtech.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to book time for a free analysis.Subscribe to our Youtube Channelhttps://www.youtube.com/@thestateofmedtechSubscribe to our LinkedIn Newsletterhttps://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/Follow The State of MedTech onLinkedIn https://www.linkedin.com/company/thestateofmedtech/Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/stateofmedtech/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@stateofmedtechpodX https://x.com/stateofmedtechFacebook ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/stateofmedtechFollow Omar M. Khateeb onLinkedIn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/okhateeb/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/omar.m.khateeb/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok https://www.tiktok.com/@omar.m.khateebX ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https: https://x.com/OmarMKhateebFacebook ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/OmarMKhateeb#MedTech #HealthcareInnovation #MedicalDevices #VentureCapital #DigitalHealth